NCT00641160View on ClinicalTrials.gov

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Nonhematologic Malignancies
Interventions
DRUG

vinorelbine tartrate

Dose Level #1 PO for at least 7 days

DRUG

vinorelbine tartrate

Dose Level #2 PO for at least 7 days

DRUG

vinorelbine tartrate

Dose Level #3 PO for at least 7 days

Trial Locations (1)

75246

Texas Oncology PA; Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Metronome Therapeutics

INDUSTRY